Page 35 - Read Online

Page 14 of 15 Allen et al. Hepatoma Res 2021;7:73 https://dx.doi.org/10.20517/2394-5079.2021.98

40. Neoptolemos JP, Moore MJ, Cox TF, et al; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with
fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the
ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308:147-56. DOI PubMed
41. Ebata T, Hirano S, Konishi M, et al; Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant
gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018;105:192-202. DOI PubMed
42. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer
(PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658-67. DOI PubMed
43. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a
randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73. DOI PubMed
44. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin
Oncol 2019;37:1015-27. DOI PubMed
45. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine
followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol
2015;33:2617-22. DOI PubMed PMC
46. Al-batran S, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel
versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction
adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57. DOI PubMed
47. Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review
and meta-analysis. JAMA Netw Open 2020;3:e2030097. DOI PubMed PMC
48. Versteijne E, Suker M, Groothuis K, et al; Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery
for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol
2020;38:1763-73. DOI PubMed PMC
49. Ercolani G, Vetrone G, Grazi GL, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment
of recurrence significantly prolong survival. Ann Surg 2010;252:107-14. DOI PubMed
50. Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched
analysis. Eur J Surg Oncol 2019;45:1432-8. DOI PubMed
51. Mcmasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg
1997;174:605-9. DOI PubMed
52. Katayose Y, Nakagawa K, Yoshida H, et al. Neoadjuvant chemoradiation therapy for cholangiocarcinoma to improve R0 resection
rate: the first report of phase II study. J Clin Oncol 2015;33:402-402. DOI
53. Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable"
gallbladder cancer: the need to define indications. HPB (Oxford) 2018;20:841-7. DOI PubMed
54. De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant
chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-16. DOI PubMed
55. Zaborowski A, Heneghan HM, Fiore B, et al. Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar
cholangiocarcinoma: the irish experience of the mayo protocol. Transplantation 2020;104:2097-104. DOI PubMed
56. Goetze TO, Bechstein WO, Bankstahl US, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver
resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder
carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry
of incidental gallbladder carcinoma platform (GR) - the AIO/CALGP/ACO-GAIN-trial. BMC Cancer 2020;20:122. DOI PubMed
PMC
57. Engineer R, Patkar S, Lewis SC, et al. A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus
chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol. BMJ Open 2019;9:e028147. DOI PubMed
PMC
58. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-
704. DOI PubMed
59. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 2020;382:1894-905. DOI PubMed
60. Finn RS, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study
of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma
(HCC). J Clin Oncol 2021;39:267. DOI
61. Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev
2021;95:102170. DOI PubMed
62. Kobayashi S, Miyamoto A, Shimizu J, et al. Comparison of 4-weekly vs 3-weekly gemcitabine as adjuvant chemotherapy following
curative resection for biliary tract cancer: a prospective randomized controlled trial. Journal of Cancer Therapy 2011;02:703-9. DOI
63. Cho M, Wang-Gillam A, Myerson R, et al. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent
chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford) 2015;17:587-93. DOI PubMed PMC
64. Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative
resection for biliary tract cancer. J Hepatobiliary Pancreat Sci 2015;22:789-94. DOI PubMed
65. Woo SM, Yoon K, Hong EK, et al. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for
biliary tract cancer after surgical resection: results from a phase II study. Oncotarget 2017;8:81394-404. DOI PubMed PMC